TY - JOUR
T1 - Synthesis and Biochemical Evaluation of Noncyclic Nucleotide Exchange Proteins Directly Activated by cAMP 1 (EPAC1) Regulators
AU - Wang, Pingyuan
AU - Luchowska-Stańska, Urszula
AU - Van Basten, Boy
AU - Chen, Haiying
AU - Liu, Zhiqing
AU - Wiejak, Jolanta
AU - Whelan, Padraic
AU - Morgan, David
AU - Lochhead, Emma
AU - Barker, Graeme
AU - Rehmann, Holger
AU - Yarwood, Stephen J.
AU - Zhou, Jia
N1 - Publisher Copyright:
© 2020 American Chemical Society.
PY - 2020/5/28
Y1 - 2020/5/28
N2 - Exchange proteins directly activated by cAMP (EPAC) play a central role in various biological functions, and activation of the EPAC1 protein has shown potential benefits for the treatment of various human diseases. Herein, we report the synthesis and biochemical evaluation of a series of noncyclic nucleotide EPAC1 activators. Several potent EPAC1 binders were identified including 25g, 25q, 25n, 25u, 25e, and 25f, which promote EPAC1 guanine nucleotide exchange factor activity in vitro. These agonists can also activate EPAC1 protein in cells, where they exhibit excellent selectivity toward EPAC over protein kinase A and G protein-coupled receptors. Moreover, 25e, 25f, 25n, and 25u exhibited improved selectivity toward activation of EPAC1 over EPAC2 in cells. Of these, 25u was found to robustly inhibit IL-6-activated signal transducer and activator of transcription 3 (STAT3) and subsequent induction of the pro-inflammatory vascular cell adhesion molecule 1 (VCAM1) cell-adhesion protein. These novel EPAC1 activators may therefore act as useful pharmacological tools for elucidation of EPAC function and promising drug leads for the treatment of relevant human diseases.
AB - Exchange proteins directly activated by cAMP (EPAC) play a central role in various biological functions, and activation of the EPAC1 protein has shown potential benefits for the treatment of various human diseases. Herein, we report the synthesis and biochemical evaluation of a series of noncyclic nucleotide EPAC1 activators. Several potent EPAC1 binders were identified including 25g, 25q, 25n, 25u, 25e, and 25f, which promote EPAC1 guanine nucleotide exchange factor activity in vitro. These agonists can also activate EPAC1 protein in cells, where they exhibit excellent selectivity toward EPAC over protein kinase A and G protein-coupled receptors. Moreover, 25e, 25f, 25n, and 25u exhibited improved selectivity toward activation of EPAC1 over EPAC2 in cells. Of these, 25u was found to robustly inhibit IL-6-activated signal transducer and activator of transcription 3 (STAT3) and subsequent induction of the pro-inflammatory vascular cell adhesion molecule 1 (VCAM1) cell-adhesion protein. These novel EPAC1 activators may therefore act as useful pharmacological tools for elucidation of EPAC function and promising drug leads for the treatment of relevant human diseases.
UR - http://www.scopus.com/inward/record.url?scp=85085586005&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085586005&partnerID=8YFLogxK
U2 - 10.1021/acs.jmedchem.9b02094
DO - 10.1021/acs.jmedchem.9b02094
M3 - Article
C2 - 32340447
AN - SCOPUS:85085586005
SN - 0022-2623
VL - 63
SP - 5159
EP - 5184
JO - Journal of medicinal chemistry
JF - Journal of medicinal chemistry
IS - 10
ER -